Editor: What To Know
- , a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrint’s Ultra-Low risk threshold can identify postmenopausal breast cancer patients who will have an excellent prognosis with limited or no tamoxifen treatment.
- In this analysis, researchers sought to validate whether the MammaPrint Ultra-Low risk category can accurately identify postmenopausal, node-negative breast cancer patients who would have an excellent survival rate after surgery with no chemotherapy and a limited duration of or even no endocrine therapy.
- Agendia notes this study confirms findings from the STO-3 Trial, previously published in 2017 in JAMA Oncology, and continues to show that the use of MammaPrint to stratify patient populations could help prevent the overtreatment of breast cancer patients.
September 17, 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrint’s Ultra-Low risk threshold can identify postmenopausal breast cancer patients who will have an excellent prognosis with limited or no tamoxifen treatment.
The presentation, “Avoid systemic overtreatment of postmenopausal breast cancer patients with Ultralow MammaPrint result,” can be found in the ESMO virtual exhibit.
Adjuvant anti-estrogen therapy is a widely-used therapy for estrogen receptor positive breast cancers, but as with many cancer treatments, may cause serious side effects. In this analysis, researchers sought to validate whether the MammaPrint Ultra-Low risk category can accurately identify postmenopausal, node-negative breast cancer patients who would have an excellent survival rate after surgery with no chemotherapy and a limited duration of or even no endocrine therapy.
Agendia notes this study confirms findings from the STO-3 Trial, previously published in 2017 in JAMA Oncology, and continues to show that the use of MammaPrint to stratify patient populations could help prevent the overtreatment of breast cancer patients.
“These data are particularly exciting because they continue to demonstrate utility for MammaPrint in the clinically low risk patient population. The study suggests that we may be able to de-escalate endocrine treatment for these patients,” said William Audeh, MD, MS, Chief Medical Officer at Agendia. “We are pleased to present results that illustrate not only the potential of MammaPrint to identify which patients may be spared chemotherapy, but also to indicate patients who may not require five years, and certainly not ten years, of endocrine therapy. These data could be used to spare some women with ultra-low risk breast cancer from being over-treated.”
Agendia is committed to providing immediate, actionable data points and furthering research that will allow for breast cancer patients and their care teams to confidently make the most personalized treatment decisions.
